New Data from Genentech Inc. Illuminate Findings in Liver Cancer (Imbrave152/skyscraper-14: a Phase Iii Study of Atezolizumab, Bevacizumab and Tiragolumab In Advanced Hepatocellular Carcinoma).

A recent study conducted by Genentech Inc. in South San Francisco has shed light on the potential benefits of a new treatment combination for advanced hepatocellular carcinoma (HCC), a type of liver cancer. The study focuses on the use of atezolizumab, bevacizumab, and tiragolumab in patients with HCC who have not received prior systemic treatment. Atezolizumab and bevacizumab are already used together as a standard treatment for liver cancer, and tiragolumab is designed to block the TIGIT receptor, which may enhance the immune response against the tumor. The study aims to determine if this new combination can improve patient outcomes compared to the standard treatment. Safety and patient experience during the treatment are also important considerations in the study. [Extracted from the article]